Projectgroup
The TUBA-WISP II study is a collaboration between the TUBA study group and the WISP trial group. The TUBA study group is located at the Radboud university medical center in Nijmegen, The Netherlands and led by Dr. Joanne de Hullu. The WISP trial group is founded by Prof. Dr. Karen Lu at the MD Anderson Cancer Center, Houston, Texas, USA.
The TUBA-WISP II project team:
- Dr. Joanne de Hullu, gynaecologic oncologist Radboudumc
- Prof. Dr. Rosella Hermens, IQ Healthcare Radboudumc
- Prof. Dr. Karen Lu, department of gynecologic oncology and reproductive medicine MD Anderson
- Prof. Dr. Elizabeth Swisher, department of gynecologic oncology University of Washington, Seattle
- Dr. Miranda Steenbeek, fellow gynaecologic oncology in the Catharina Hospital Eindhoven and Radboudumc
- Dr. Majke van Bommel, fertility doctor Radboudumc
- Drs. Tamar Gootzen, PhD candidate Radboudumc
The study was further developed together with statisticians: Prof. Kit Roes and Dr. Joanna IntHout (both Radboudumc) and Dr. Gary Chisholm and Dr. Christine Peterson (both MD Anderson); pathologists (Dr. Hans Bulten and Dr. Michiel Simons) and healthcare specialists.

Joanne de Hullu

Elizabeth Swisher

Karen Lu

Miranda Steenbeek

Tamar Gootzen

Rosella Hermens

Majke van Bommel
Participating centers
Last update: January 14th, 2025

The Netherlands















United States of America









Norway



Italy



Poland




Belgium


Sweden

Uruguay

Mexico

Australia









Brazil

Austria

Canada

Patient societies
The following patient organizations are supporting this study:
- The Dutch patient organization for hereditary cancer, a part of the Dutch Breast Cancer Society 'Stichting Erfelijke Kanker Nederland' (in English: Foundation Hereditary Cancer; previously called 'Oncogen')
- The Dutch patient organization for women with gynaecological cancer 'Olijf'
- The Patient Advisory Board 'Women's Cancer' of the Radboudumc



Funding
